1571P COVID-19 positivity rates in patients with an active cancer diagnosis in the University of California Cancer Consortium. Read more about 1571P COVID-19 positivity rates in patients with an active cancer diagnosis in the University of California Cancer Consortium.
512O Interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignancies. Read more about 512O Interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignancies.
Resilience of elective cancer surgery systems during COVID-19 lockdowns: International, prospective cohort study of planned surgery for 15 tumour types in 61 countries Read more about Resilience of elective cancer surgery systems during COVID-19 lockdowns: International, prospective cohort study of planned surgery for 15 tumour types in 61 countries
APOBEC signatures and high tumour mutational burden as predictors of clinical outcomes and response to therapy in patients with urothelial carcinoma. Read more about APOBEC signatures and high tumour mutational burden as predictors of clinical outcomes and response to therapy in patients with urothelial carcinoma.
O4.2 Development of novel small molecule MerTK and Flt3 tyrosine kinase inhibitors for treatment of acute leukemia. Read more about O4.2 Development of novel small molecule MerTK and Flt3 tyrosine kinase inhibitors for treatment of acute leukemia.
